AU2003208946A1 - Anti-interleukin-1 beta analogs - Google Patents

Anti-interleukin-1 beta analogs

Info

Publication number
AU2003208946A1
AU2003208946A1 AU2003208946A AU2003208946A AU2003208946A1 AU 2003208946 A1 AU2003208946 A1 AU 2003208946A1 AU 2003208946 A AU2003208946 A AU 2003208946A AU 2003208946 A AU2003208946 A AU 2003208946A AU 2003208946 A1 AU2003208946 A1 AU 2003208946A1
Authority
AU
Australia
Prior art keywords
interleukin
beta analogs
analogs
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003208946A
Other languages
English (en)
Other versions
AU2003208946A8 (en
Inventor
John Michael Beals
Lihua Huang
Jirong Lu
Danise Paige Rogers
Derrick Ryan Witcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003208946A8 publication Critical patent/AU2003208946A8/xx
Publication of AU2003208946A1 publication Critical patent/AU2003208946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003208946A 2002-02-28 2003-02-20 Anti-interleukin-1 beta analogs Abandoned AU2003208946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36142302P 2002-02-28 2002-02-28
US60/361,423 2002-02-28
PCT/US2003/003117 WO2003073982A2 (en) 2002-02-28 2003-02-20 Anti-interleukin-1 beta analogs

Publications (2)

Publication Number Publication Date
AU2003208946A8 AU2003208946A8 (en) 2003-09-16
AU2003208946A1 true AU2003208946A1 (en) 2003-09-16

Family

ID=27789118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003208946A Abandoned AU2003208946A1 (en) 2002-02-28 2003-02-20 Anti-interleukin-1 beta analogs

Country Status (5)

Country Link
US (1) US20050070692A1 (de)
EP (1) EP1481010A2 (de)
JP (1) JP2005518802A (de)
AU (1) AU2003208946A1 (de)
WO (1) WO2003073982A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004207741B2 (en) * 2003-01-24 2011-02-10 Applied Molecular Evolution, Inc Human IL-1 beta antagonists

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
JP2006315964A (ja) * 2005-05-10 2006-11-24 Chugai Pharmaceut Co Ltd 抗体安定化方法
ES2827247T3 (es) 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
CN101522717A (zh) * 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
EP3124045A3 (de) 2006-12-20 2017-05-03 Xoma (Us) Llc Behandlung von il-1-beta-bedingten erkrankungen
EP2604278B1 (de) 2007-01-11 2017-04-12 Novo Nordisk A/S Antikörper gegen kir, formulierungen und anwendungen davon
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
WO2010028273A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
AR078650A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Anticuerpo de union a il-1 beta
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
SG185473A1 (en) 2010-05-07 2012-12-28 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
JP5918275B2 (ja) * 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
KR20170082594A (ko) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
JP6787888B2 (ja) * 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
AR128222A1 (es) * 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
US5202422A (en) * 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5479514A (en) * 1994-02-23 1995-12-26 International Business Machines Corporation Method and apparatus for encrypted communication in data networks
KR100473536B1 (ko) * 1996-05-22 2005-05-16 마츠시타 덴끼 산교 가부시키가이샤 기기간통신의안전성을확보하는암호화장치및통신시스템
US6041123A (en) * 1996-07-01 2000-03-21 Allsoft Distributing Incorporated Centralized secure communications system
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1423432A4 (de) * 2001-07-26 2006-01-11 Lilly Co Eli Interleukin-1-beta-antikörper

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004207741B2 (en) * 2003-01-24 2011-02-10 Applied Molecular Evolution, Inc Human IL-1 beta antagonists

Also Published As

Publication number Publication date
WO2003073982A3 (en) 2004-02-26
AU2003208946A8 (en) 2003-09-16
JP2005518802A (ja) 2005-06-30
WO2003073982A2 (en) 2003-09-12
US20050070692A1 (en) 2005-03-31
EP1481010A2 (de) 2004-12-01

Similar Documents

Publication Publication Date Title
EP2295053B8 (de) Neue 2H-Chromen-2-one-3-carboxamide für medizinische Verwendungen
AU2003266949A1 (en) Compounds
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003239690A1 (en) Jettable compositions
AU2003208946A1 (en) Anti-interleukin-1 beta analogs
AU2003207491A1 (en) High fat/fiber composition
AU2002319899A1 (en) Novel resveratrol analogs
AU2003279366A1 (en) Novel compounds
AU2003259290A1 (en) Glass compositions
WO2003072535A8 (en) Substituted hydroxyethylamines
AUPS032202A0 (en) Teether
AU2003227792A1 (en) Lignan formulations
AU2003238043A1 (en) Substituted imidazotriazines
EP1493437A4 (de) Zusammensetzungen für diabetes
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003211453A1 (en) External compositions for the skin
AU2002950744A0 (en) Composition
AU2003252694A1 (en) External preparation
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003252683A1 (en) Composition for oral use
AU2003218170A1 (en) Autoinducer compounds
AU2003269904A1 (en) Antigen-polymer compositions
AU2003208411A1 (en) Anti-glycolytic composition
AU2003216859A1 (en) Amidoacetonitrile compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase